<code id='9B72089E4F'></code><style id='9B72089E4F'></style>
    • <acronym id='9B72089E4F'></acronym>
      <center id='9B72089E4F'><center id='9B72089E4F'><tfoot id='9B72089E4F'></tfoot></center><abbr id='9B72089E4F'><dir id='9B72089E4F'><tfoot id='9B72089E4F'></tfoot><noframes id='9B72089E4F'>

    • <optgroup id='9B72089E4F'><strike id='9B72089E4F'><sup id='9B72089E4F'></sup></strike><code id='9B72089E4F'></code></optgroup>
        1. <b id='9B72089E4F'><label id='9B72089E4F'><select id='9B72089E4F'><dt id='9B72089E4F'><span id='9B72089E4F'></span></dt></select></label></b><u id='9B72089E4F'></u>
          <i id='9B72089E4F'><strike id='9B72089E4F'><tt id='9B72089E4F'><pre id='9B72089E4F'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:knowledge    Page View:7274

          Which presentations are worth catching at ASCO this weekend? What is exon-skipping? And how do you pronounce bronchiectasis?

          This week on “The Readout LOUD,” we preview some of the research that will be presented at the American Society of Clinical Oncology conference in Chicago. We also discuss the latest news in the health and life sciences, including a milestone in lung disease R&D and a Duchenne muscular dystrophy confirmatory trial failure.  

          advertisement

          To read more about Merus’ combination therapy, go here; For more on Johnson & Johnson’s mixed data, click here; For more on Nippon Shinyaku’s Duchenne drug trial failure, go here; To read more on Insmed’s bronchiectasis treatment, click here; To sign up for STAT’s ASCO newsletter, click here.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          comprehensive

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          Dexcom's push to bring CGM to type 2 diabetes patients
          Dexcom's push to bring CGM to type 2 diabetes patients

          KevinSayer,CEOofDexcomDexcomForyears,diabetestechcompanyDexcomhasbeenstrivingtogetitscontinuousgluco

          read more
          Walensky prepares to leave CDC — and Congress — behind
          Walensky prepares to leave CDC — and Congress — behind

          OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

          read more

          Zyn nicotine pouches become unlikely player in latest culture war

          WikimediaCommonsSenateMajorityLeaderChuckSchumer(D-N.Y.)wantsthefederalgovernmenttoinvestigateZynnic